Gas Usage for Those With COPD Who Experience Low Oxygen Levels During Activities Only
Chronic Obstructive Pulmonary DiseaseSeveral studies have described the use of supplemental oxygen during exertion or activities of daily living (ambulatory oxygen) in study populations that have different characteristics. This report, based on specialized randomized controlled trials, characterizes ambulatory gas usage among patients with COPD who experience low oxygen levels during activities.
A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With...
Chronic Obstructive Pulmonary DiseaseThis study was conducted to provide detailed information on the efficacy of indacaterol in terms of its effect on spirometry assessed forced expiratory volume in 1 second (FEV1) over a 24 hour time period.
Safety of Exercise and High-dose Salbutamol in Patients With Chronic Obstructive Pulmonary Disease...
Chronic Obstructive Pulmonary DiseaseThis study investigated the effect of exercise and high-dose salbutamol on the maximum heart rate in patients with chronic obstructive pulmonary disease (COPD) receiving therapeutic doses of indacaterol, salmeterol and placebo.
Arm Training in Patients With Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary DiseasePatients with chronic lung disease often report shortness of breath when they use their arms for simple activities of daily living such as dressing, lifting, shaving, bathing and brushing their hair and teeth. The best type of arm training for these patients is still unknown. The objectives of this study are to: develop a feasible and safe arm training program (ATP) for these patients; examine the effects of this ATP on quality of life, arm function, arm exercise capacity and symptoms during activities of daily living; examine the effects of ATP on breathing responses during arm exercises.
Efficacy and Safety of Levalbuterol in Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease (COPD)To investigate the efficacy and safety of repeated dosing of Levalbuterol over 6 weeks of treatment in COPD.
A Pivotal Study of the Safety and Effectiveness of Arformoterol in Subjects With Chronic Obstructive...
COPDA 12 week study to investigate the safety and effectiveness of arformoterol given twice daily compared to placebo in subjects with COPD.
Effectiveness and Safety of BIO-11006 Inhalation Solution to Treat the Overproduction of Mucus and...
COPDChronic Obstructive Pulmonary DiseaseThe symptoms associated with COPD include overproduction of mucus and inflammation in the lungs. Overproduction of mucus results in impaired lung function and it encourages bacterial growth and associated COPD exacerbations. Therefore, a treatment that inhibits mucus overproduction or blocks inflammation could benefit COPD patients. The drug under evaluation in this study, BIO-11006 Inhalation Solution, is a new drug that may inhibit overproduction of mucus and may have important anti-inflammatory properties.
Lovastatin as a Potential Modulator of Apoptosis in Chronic Obstructive Pulmonary Disease (COPD)...
Chronic Obstructive Pulmonary Disease (COPD)This study will test whether lovastatin helps to modify lung inflammation in patients with COPD (Chronic Obstructive Pulmonary Disease).
Safety, Tolerability, and Pharmacodynamic Effect Study of PUR118
Chronic Obstructive Pulmonary DiseaseThe purpose of this study is to establish single and multiple dose safety in healthy subjects and subjects with mild chronic pulmonary obstructive disease (COPD). In addition, the study will evaluate preliminary proof of concept endpoints in COPD subjects such as biomarkers in sputum and mucociliary clearance.
Safety, Tolerability and Pharmacokinetics of QAK423A in Healthy Volunteers and Chronic Obstructive...
Chronic Obstructive Pulmonary DiseaseThere are three elements to this study: Part A: Single dose escalation in healthy subjects. 6 dose levels of QAK423 are planned in healthy volunteers. Part B: Single dose escalation in patients with mild/moderate COPD. 3 dose levels of QAK423 are planned in COPD patients. Part C: Titrated repeat dosing for a maximum of 14 days in mild/moderate COPD patients. Repeat dosing is planned in COPD patients.